Decoy Therapeutics (NASDAQ:DCOY) Sees Significant Decrease in Short Interest

Decoy Therapeutics (NASDAQ:DCOY) saw a large drop in short interest in the month of April. As of April 30th, there was short interest totaling 11,279 shares, a drop of 51.5% from the April 15th total of 23,252 shares. Approximately 2.1% of the shares of the company are short sold. Based on an average daily trading volume, of 13,202 shares, the short-interest ratio is currently 0.9 days.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on DCOY shares. Wall Street Zen raised shares of Decoy Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, February 21st. Weiss Ratings raised shares of Decoy Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a report on Thursday, May 7th. Finally, LADENBURG THALM/SH SH started coverage on shares of Decoy Therapeutics in a report on Friday, January 23rd. They issued a “buy” rating and a $30.00 price objective for the company. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $30.00.

Decoy Therapeutics Price Performance

NASDAQ:DCOY traded down $0.11 during trading hours on Friday, hitting $4.41. The stock had a trading volume of 6,085 shares, compared to its average volume of 10,795. The business’s 50 day moving average price is $6.36. Decoy Therapeutics has a one year low of $4.32 and a one year high of $415.80. The stock has a market cap of $2.34 million, a price-to-earnings ratio of -0.04 and a beta of 0.38.

Decoy Therapeutics (NASDAQ:DCOY) last announced its quarterly earnings results on Friday, May 8th. The company reported ($4.18) EPS for the quarter. Research analysts predict that Decoy Therapeutics will post -12.97 EPS for the current year.

Decoy Therapeutics Company Profile

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577.